Watch WST. Know when insiders buy.
One email the day a filing lands. Free.
WST
WEST PHARMACEUTICAL SERVICES INC
392.15
−1.88 −0.48%
USD · close Oct 23
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
34
FLAG · insiders 25, shorts 42
Insiders, 90 days
−$5.4M
net selling · 0 buys, 6 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $27.6BP/E 50.2DIV YIELD —FCF YIELD 1.58%REV TTM $3.3B +12.4%NET INCOME $564.9M +15.8%NET CASH $232.9M52W 230.95 – 394.03SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $872.3M | +13.8% | 37.7% | $179.1M | $154M | +16.8% | 2.15 | $124M | $43.2M | $80.8M | Jul 23 |
| Q1 2026 · Mar 31 | $844.9M | +21.0% | 35.1% | $177.1M | $138.8M | +54.6% | 1.92 | $89.9M | $42.7M | $47.2M | Jul 23 |
| Q4 2025 · Dec 31derived | $805M | +7.5% | 37.8% | $156.6M | $132.1M | +1.5% | 1.82 | $251.1M | $76.1M | $175M | Feb 17 |
| Q3 2025 · Sep 30 | $804.6M | +7.7% | 36.6% | $167.6M | $140M | +2.9% | 1.92 | $197.2M | $63.3M | $133.9M | Oct 23 |
| Q2 2025 · Jun 30 | $766.5M | +9.2% | 35.7% | $153.7M | $131.8M | +18.4% | 1.82 | $177.1M | $75.2M | $101.9M | Jul 23 |
| Q1 2025 · Mar 31 | $698M | +0.4% | 33.2% | $107M | $89.8M | −22.1% | 1.23 | $129.4M | $71.3M | $58.1M | Jul 23 |
| Q4 2024 · Dec 31derived | $748.8M | +2.3% | 36.5% | $159.6M | $130.1M | −5.0% | 1.78 | $190.1M | $104.9M | $85.2M | Feb 17 |
| Q3 2024 · Sep 30 | $746.9M | −0.1% | 35.4% | $161.3M | $136M | −15.7% | 1.85 | $180.1M | $81.3M | $98.8M | Oct 23 |
| Q2 2024 · Jun 30 | $702.1M | — | 32.8% | $126.2M | $111.3M | — | 1.51 | $165M | $100.2M | $64.8M | Oct 23 |
| Q1 2024 · Mar 31 | $695.4M | — | 33.1% | $122.8M | $115.3M | — | 1.55 | $118.2M | $90.6M | $27.6M | Oct 23 |
| Q4 2023 · Dec 31derived | $732M | — | 38.0% | $160.9M | $137M | — | 1.83 | $239.1M | $108.7M | $130.4M | Feb 17 |
| Q3 2023 · Sep 30 | $747.4M | — | 38.6% | $177.3M | $161.3M | — | 2.14 | $230.1M | $95.8M | $134.3M | Oct 24 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $3.1B | 35.9% | $584.9M | $493.7M | 16.1% | 6.79 | $754.8M | $285.9M | $468.9M | $134M | $61.2M |
| FY2024 · to Dec 31 | $2.9B | 34.5% | $569.9M | $492.7M | 17.0% | 6.69 | $653.4M | $377M | $276.4M | $560.9M | $59.1M |
| FY2023 · to Dec 31 | $2.9B | 38.3% | $676M | $593.4M | 20.1% | 7.88 | $776.5M | $362M | $414.5M | $438.3M | $57M |
| FY2022 · to Dec 31 | $2.9B | 39.4% | $734M | $585.9M | 20.3% | 7.73 | $724M | $284.6M | $439.4M | $202.8M | $54.1M |
| FY2021 · to Dec 31 | $2.8B | 41.5% | $752.3M | $661.8M | 23.4% | 8.67 | $584M | $253.4M | $330.6M | $137.1M | $51.1M |
| FY2020 · to Dec 31 | $2.1B | 35.8% | $406.9M | $346.2M | 16.1% | 4.57 | $472.5M | $174.4M | $298.1M | $115.5M | $48.1M |
Every number comes from WEST PHARMACEUTICAL SERVICES INC's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.